The Predictive Value of Inflammation-Related Peripheral Blood Measurements in Cancer Staging and Prognosis

Sylman, Joanna L.; Mitrugno, Annachiara; Atallah, Michelle; Tormoen, Garth W.; Shatzel, Joseph J.; Yunga, Samuel Tassi; Wagner, Todd H.; Leppert, John T.; Mallick, Parag; McCarty, Owen J. T.

doi:10.3389/fonc.2018.00078

Cited by 80 publications

(61 citation statements)

References 136 publications

(114 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients ( from the tumor microenvironment and can be assessed by biomarkers or used as a prognostic factor across many malignancies, including BC. Besides NLR, other inflammation related biomarkers have been evaluated in BC progression including platelet counts, body mass index or ultra-sensitive C-reactive protein (Sylman et al, 2018). As a marker for systemic inflammation, elevated NLR levels are also present in infection-derived inflammatory processes.…”

Section: Characteristicsmentioning

confidence: 99%

The Neutrophil to Lymphocyte Ratio Predicts the Response to Neoadjuvant Chemotherapy in Luminal B Breast Cancer

Rivas

Acevedo

Domı́nguez

et al. 2019

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Objective: Tumor response to neoadjuvant chemotherapy (NAC) in breast cancer (BC) patients is a predictor for overall survival. The aim of our study was to determine a relationship between the neutrophil to lymphocyte ratio (NLR) prior to NAC, BC subtypes and the probability of a pathologic complete response (pCR). Materials and Methods: Medical records were collected retrospectively from Centro de Cancer at Red Salud UC-Christus. Clinical data collected included peripheral blood cell counts, BC subtype at diagnosis and the pathology report of surgery after chemotherapy. Results: A total of 88 patients were analyzed. Approximately, a 25% had a pCR, and displayed a significant correlation between BC subtype and pCR (p= 0.0138 Chi2); this was more frequent in epidermal growth factor receptor type 2 (HER2) enriched subtype patients (54%). Luminal B BC patients with a pCR had significantly lower NLR levels (t test, p= 0.0181). Conclusions: HER2-enriched tumors had a higher probability of pCR. In Luminal B tumors, NLR had a statistically significant relationship with the probability of pCR. In this subtype, NLR could be a useful biomarker to predict tumor response to NAC. Further studies including other clinical parameters for systemic inflammation such as platelet counts, intratumoral NLR or body mass index could help identify patients that would get the most benefit from NAC.

show abstract

Section: Characteristicsmentioning

confidence: 99%

The Neutrophil to Lymphocyte Ratio Predicts the Response to Neoadjuvant Chemotherapy in Luminal B Breast Cancer

Rivas

Acevedo

Domı́nguez

et al. 2019

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…A systemic inflammatory index such as neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), or platelet to lymphocyte ratio (PLR) has been associated with poor prognosis in several cancers (9,10). Studies have demonstrated an association between high NLR and MLR, and poor overall and recurrence free survival in resected PNETs (11,12).…”

Section: Background and Rationale For The Studymentioning

confidence: 99%

Role of Pre-operative Inflammatory Markers as Predictors of Lymph Node Positivity and Disease Recurrence in Well-Differentiated Pancreatic Neuroendocrine Tumours: Pancreas2000 Research and Educational Program (Course 9)

Tanno

Pea²,

Nykänen

et al. 2020

Front. Med.

View full text Add to dashboard Cite

Pancreatic neuroendocrine tumours (PNET) is a rare disease and in the absence of metastases, surgical resection is recommended. Key factors affecting survival in PNETs are the stage and grade of the disease, but there is increasing evidence suggesting lymph node involvement is associated with shorter disease-free and overall survival. Ability to predict the likelihood of lymph node involvement at the time of diagnosis would affect surgical decision making in these patients. A systemic inflammatory index such as neutrophil to lymphocyte ratio or platelet to lymphocyte ratio has been associated with poor prognosis in several cancers. Method: This study is a retrospective multi-centre study. The data including pre-operative inflammatory markers such as haemoglobin, neutrophil, lymphocyte counts and pathological data including number of positive lymph nodes, tumour grade and size, are collected to assess the association between inflammatory index and lymph node involvement. Conclusion: This study aims to assess the value of routinely available pre-operative haematological markers in predicting lymph node involvement in non-functioning PNETs.

show abstract

“…4,5 However, despite these advancements, the morbidity and death rates of HCC are increasing. 9,10 Currently, the CRP/albumin (Alb) ratio (CAR) has been identified as a new prognostic marker. Serum markers, with their general availability and affordability, are useful for predicting HCC recurrence and survival.…”

Section: Introductionmentioning

confidence: 99%

“…8 Some proposed inflammatory indicators, including the neutrophil/lymphocyte ratio (NLR), the platelet/lymphocyte ratio (PLR), and the C-reactive protein (CRP) level, have been demonstrated to be useful indicators for evaluating the prognosis of the disease and survival of various cancers. 9,10 Currently, the CRP/albumin (Alb) ratio (CAR) has been identified as a new prognostic marker. An increased CAR is related to an unfavorable prognosis of various cancers, for example, cervical cancer and esophageal cancer.…”

Section: Introductionmentioning

confidence: 99%

Prognostic significance of the CRP/Alb and neutrophil to lymphocyte ratios in hepatocellular carcinoma patients undergoing TACE and RFA

Shen

Wang

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background The C‐reactive protein (CRP)/albumin (Alb) ratio (CAR) is a basic inflammatory factor that has been related to poor survival of patients with various tumors. Our research retrospectively examined the relationship between the CAR and the prognosis of hepatocellular carcinoma (HCC). Methods This study included 172 patients with HCC who were treated with transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA). Results The CAR was weakly related to the neutrophil/lymphocyte ratio (NLR, r = .159, P = .037) and the lymphocyte/monocyte ratio (LMR, r = −.263, P = .001). The Glasgow Prognostic Score (GPS) (0/1‐2) was related to liver cirrhosis (P = .003), tumor number (P = .02), Child‐Pugh grade (P = .001), the platelet/lymphocyte ratio (PLR, P = .006), and the LMR (P = .021). Correlation analysis demonstrated that an elevated CAR was markedly correlated with the tumor size (P = .019), alpha‐fetoprotein (AFP) level (P = .033), thrombosis of the portal vein (P = .004), the NLR (P = .036), and the LMR (P = .001). Multivariate analysis indicated that the prognosis of the CAR‐High and NLR‐High cohort (mOS = 7 months) was significantly worse than those of the CAR‐High or NLR‐High cohort (mOS = 15 months) and the CAR‐Low and NLR‐Low cohort (mOS = 26.5 months). Conclusions Combination of the NLR and the CAR represents a convenient, quick, and noninvasive biological marker that could improve prognostic prediction in patients with HCC.

show abstract

The Predictive Value of Inflammation-Related Peripheral Blood Measurements in Cancer Staging and Prognosis

Cited by 80 publications

References 136 publications

The Neutrophil to Lymphocyte Ratio Predicts the Response to Neoadjuvant Chemotherapy in Luminal B Breast Cancer

The Neutrophil to Lymphocyte Ratio Predicts the Response to Neoadjuvant Chemotherapy in Luminal B Breast Cancer

Role of Pre-operative Inflammatory Markers as Predictors of Lymph Node Positivity and Disease Recurrence in Well-Differentiated Pancreatic Neuroendocrine Tumours: Pancreas2000 Research and Educational Program (Course 9)

Prognostic significance of the CRP/Alb and neutrophil to lymphocyte ratios in hepatocellular carcinoma patients undergoing TACE and RFA

Contact Info

Product

Resources

About